Granules India Limited (GRANULES) fell -5% to ₹829.1 on the NSE on 22 Jul 2026, backed by its Q1 FY27 results where revenue surged 22% YoY and PAT jumped 60%. The stock’s decline today can be attributed to the shift in trendline status from CONSOLIDATING UP to APPROACHING RESISTANCE, with the stock now just 1.0% away from the resistance level at ₹837. This move is also notable as the stock is currently 10% above its 50-DMA, indicating a stretched position. In the healthcare sector, specifically within drug manufacturers, Granules India’s performance reflects strong financial results but also highlights the stock’s sensitivity to technical levels and market sentiment.

Technical setup — trendlines & DMA

From a technical perspective, Granules India’s current price is navigating a critical juncture. The 6M support trendline is established at ₹762.53, which is 8.03% below today’s price, providing a solid floor. Conversely, the resistance trendline ends at ₹837.06, just 0.96% above the current price, indicating imminent resistance. The 50-DMA at ₹795.2 is below the current price, suggesting a bullish trend as the stock is trading 10.12% above this average. Additionally, the stock is significantly above the 200-DMA at ₹645.1, up 35.75%, reinforcing the bullish sentiment. Within the 52W range of ₹432.6 to ₹910.0, the current price sits in the upper third, reflecting a strong upward move but also indicating that a substantial portion of the potential gain might already be priced in.

Fundamentals & business context

On the fundamental front, Granules India’s PE of 35.8, coupled with an 11.1% profit margin and a revenue CAGR of 5.9%, suggests that the stock is trading at a premium relative to its earnings growth. This valuation might reflect market expectations of future growth, possibly driven by the company’s robust Q1 FY27 performance. The institutional holding of 21.0% indicates a moderate level of confidence from smart money, though not overwhelmingly bullish. There is no specific NSE catalyst today beyond the earnings release, which already significantly impacted the stock’s movement.

Algorithmic scorecard

The algorithmic scorecard for Granules India reflects a technically strong but fundamentally weaker profile. The stock’s technical strength is underscored by its bullish trend, with the 50-day average above the 200-day average, and its breakout status, indicating strong momentum. The stock’s low volatility, as evidenced by a beta of 0.10, also suggests a stable investment with less market risk. However, the fundamental weaknesses are notable, particularly the overvalued PEG of 7.46, which indicates the stock may be expensive relative to its growth rate. Additionally, the negligible dividend yield of 0.2% offers little income for investors, potentially limiting its appeal to income-focused investors.

Company outlook

Granules India’s management has outlined several strategic initiatives and outlooks for the coming fiscal year. The company anticipates potential U.S. product launches as approvals progress, with 9 applications awaiting clearance from the Gagillapur site. They aim to maintain a working capital to sales ratio in the 33% range despite cost escalations. For the peptide CDMO business, Granules India expects EBITDA and PAT positivity from FY ’27 onwards. In terms of capital expenditure, the company plans a broad-based approach for FY ’27, including a new API facility, IT investments, and a distribution center in the U.S.A., with a planned capex in the range of INR 600-odd crores, including INR 200 crores plus for the distribution center. Additionally, there are investments planned for a brownfield manufacturing facility for peptide intermediates in India, followed by a peptide API capacity.

Get all details on GRANULES — P&L, peers, shareholding and more on TradeAlone.